While gene therapy has been a subject of extensive research for over 50 years, with more than 62,000 publications on PubMed and 1,000 registered trials on ClinicalTrials.gov, the approvals of the previous decade have been focused on rare diseases. Recent advances in vector design and nucleic acid technologies now allow for the use of gene therapy in a broad range of therapeutic indications, bringing its curative potential to common ailments, at an affordable cost. Remedium has developed Prometheus™ - a revolutionary platform that enables replacement of subcutaneously delivered proteins, as a safe, durable, and pharmacokinetically-optimized, single injection gene therapy – for a fraction of the current treatment costs.